AbCellera Biologics (ABCL) Cash from Financing Activities (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Cash from Financing Activities data on file, last reported at $7.2 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 20.47% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (down 3.8% YoY) and the FY2025 annual result came in at $14.1 million, up 10.28% from the prior year.
• Cash from Financing Activities climbed to $7.2 million in Q1 2026, from $4.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.4 million in Q3 2025 to a low of -$3.4 million in Q2 2025.
• A 5-year average of $2.5 million and a median of $2.8 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 34994.74% — and 2025, when it tumbled 227.31%.
• Tracing ABCL's Cash from Financing Activities over 5 years: stood at $349000.0 in 2022, then surged by 978.8% to $3.8 million in 2023, then gained by 10.01% to $4.1 million in 2024, then retreated by 0.65% to $4.1 million in 2025, then surged by 74.78% to $7.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $7.2 million (Q1 2026), $4.1 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.